Migraine: a Comprehensive Review of New Treatment Options
Overview
Authors
Affiliations
Headaches are among the most common complaints reported to health care professionals and are classified by the International Headache Society as migraine, tension-type, or cluster, with additional subtypes. Classification and etiology of headache should be determined after thorough review of the patient's history. Once diagnosed, migraine can be treated by preventive or abortive measures. Recent developments add new options, including availability of drugs for intranasal administration (sumatriptan, dihydroergotamine) and 5-HT1B/1D agonists (rizatriptan, zolmitriptan, naratriptan, eletriptan). Although placebo-controlled trials are available, few comparative clinical trials of these agents have been conducted; however, important pharmacologic, pharmacokinetic, and clinical differences exist among the drugs.
The pharmacological management of migraine, part 1: overview and abortive therapy.
DeMaagd G P T. 2009; 33(7):404-16.
PMID: 19750119 PMC: 2740949.
Rizatriptan: an update of its use in the management of migraine.
Wellington K, Plosker G Drugs. 2002; 62(10):1539-74.
PMID: 12093318 DOI: 10.2165/00003495-200262100-00007.
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.
Jhee S, Shiovitz T, Crawford A, Cutler N Clin Pharmacokinet. 2001; 40(3):189-205.
PMID: 11327198 DOI: 10.2165/00003088-200140030-00004.